Compass Therapeutics Sees Unusually High Options Volume (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw some unusual options trading on Friday. Stock traders acquired 4,010 call options on the company. This is an increase of 115% compared to the typical daily volume of 1,869 call options.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Thursday, October 15th. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Wedbush set a $4.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Citizens Jmp lowered their target price on shares of Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 23rd. Finally, Piper Sandler boosted their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.25.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Parallel Advisors LLC purchased a new stake in shares of Compass Therapeutics in the 1st quarter worth about $28,000. HB Wealth Management LLC acquired a new stake in Compass Therapeutics in the 2nd quarter valued at $29,000. State of Wyoming purchased a new position in shares of Compass Therapeutics during the 2nd quarter valued at approximately $31,000. Wealthcare Capital Partners LLC acquired a new position in Compass Therapeutics in the second quarter valued at approximately $43,000. Finally, Walleye Trading LLC acquired a new position in Compass Therapeutics during the 2nd quarter valued at about $55,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

NASDAQ CMPX traded up $0.03 during trading hours on Friday, reaching $0.79. The company’s stock had a trading volume of 2,916,330 shares, compared to its average volume of 4,603,215. Compass Therapeutics has a 1-year low of $0.73 and a 1-year high of $6.88. The firm has a market capitalization of $141.64 million, a price-to-earnings ratio of -1.97 and a beta of 1.02. The company’s 50-day moving average is $1.49 and its two-hundred day moving average is $3.25.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts forecast that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.